PHAXIAM Therapeutics (PHXM) 6-K ERYTECH Provides Update on theTRYbeCA-1

UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE13a-16 OR15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of April 2020

Commission File Number:001-38281

ERYTECH Pharma S.A.

(Translation of registrant’s name into English)

60 Avenue Rockefeller

69008 Lyon France

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F:

☒ Form20-F            ☐ Form40-F

Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ONFORM 6-K

Press Release

On April 20, 2020, the Company issued a press release regarding an update of theTRYbeCA-1 trial, its pivotal Phase 3 clinical trial of eryaspase for the treatment of second-line pancreatic cancer patients. A copy of the press release is attached to this Report on Form6-K as Exhibit 99.1.

EXHIBITS

Exhibit	Description
99.1	Press Release dated April 20, 2020.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ERYTECH Pharma S.A.
Date: April 21, 2020	By:	/s/ Eric Soyer
		Name Eric Soyer
		Title: Chief Financial Officer and Chief Operating Officer